Topiramate and Cerebrovascular Response in Migraineurs

Effect of Topiramate on Cerebrovascular Response to Photic Stimulation in Migraineurs

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02424318

Enrollment

Registered

2015-04-23

Start date

2008-12-31

Completion date

2010-12-31

Last updated

2015-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Disorders

Brief summary

The purpose of this study is to evaluate the effect of topiramate on cerebrovascular reactivity and mean flow velocity to photic stimulation in migraineurs.

Interventions

DRUGTopiramate

topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* aged 18 to 65 years * newly-diagnosed patients with migraine without aura (International Headache Society classification) * symptom frequency (at least 2 episodes of migraine attack/month)

Exclusion criteria

* prior use of preventive medication * patients with cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking) * patients who take antihypertensive agent or antidepressant * patients who were pregnant, breast-feeding or actively smoking * patients with neurological or cerebrovascular diseases

Design outcomes

Primary

Measure	Time frame	Description
Comparison of the Cerebrovascular reactivity	between baseline and after 2-month treatment of topiramate	Transcranial Doppler sonography (TCD) was performed twice in migraineurs before and after the topiramate treatment during their interictal period of headache. Measurements: the mean flow velocity (MFV) of the right middle cerebral artery (MCA) and the left posterior cerebral artery (PCA). After 1 minute of adaptation period to the darkness, flashlights of 10 Hz were presented using a light source of an electroencephalography machine (PS40/R-220, Grass Technologies, West Warwick, USA). Recordings were performed for 10 cycles, and each cycle consisted of 10-second stimulation-on and 10-second stimulation-off. Calculation: Cerebrovascular reactivity (CVR) CVR = Δ V/Vb or Δ V/(VbxΔT) Where Vb is the baseline MFV, Δ V/Vb is the percentage MFV increase (amplitude), ΔT is the time from the onset of the stimulation to the peak MFV, and Δ V/(VbxΔT) is the slope of the MFV increase.

Secondary

Measure	Time frame	Description
Comparison of the mean flow velocities in the middle and posterior cerebral artery	between baseline and after 2-month treatment of topiramate	Measurements: Same as outcome 1.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026